Related references
Note: Only part of the references are listed.Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon Cancer
Katherine L. Kahn et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147
S. R. Alberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected state III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147
R. M. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data
Leonard L. Gunderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Predictive Capacity of Three Comorbidity Indices in Estimating Mortality After Surgery for Colon Cancer
Robert B. Hines et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: An NCCN Institutional Analysis
Dorothy Romanus et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741
Hanna K. Sanoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07
J. Philip Kuebler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Managing older patients with colorectal cancer
Hanna Kelly Sanoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Insights into different results from different causal contrasts in the presence of effect-measure modification
Til Sturmer et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2006)
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer
Richard M. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Variable selection for propensity score models
M. Alan Brookhart et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods
T Stürmer et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2006)
Indications for propensity scores and review of their use in pharmacoepidemiology
RJ Glynn et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
Adjuvant chemotherapy for stage III colon cancer - Implications of race/ethnicity, age, and differentiation
JM Jessup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration
T Stürmer et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2005)
Capecitabine as adjuvant treatment for stage III colon cancer
C Twelves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Participation in cancer clinical trials - Race-, sex-, and age-based disparities
VH Murthy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Prognostic importance of Comorbidity in a hospital-based cancer registry
JF Piccirillo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer:: Who benefits and by how much?
S Gill et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Effectiveness of adjuvant fluorouracil in clinical practice: A population-based cohort study of elderly patients with stage III colon cancer
TJ Iwashyna et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer
V Sundararajan et al.
ANNALS OF INTERNAL MEDICINE (2002)
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients
DJ Sargent et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Development of a comorbidity index using physician claims data
CN Klabunde et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2000)
Share Paper
